Literature DB >> 26372833

Severe rash associated with vemurafenib administration following nivolumab therapy.

K Imafuku1, K Yoshino2, K Ishiwata2, S Otobe2, S Tsuboi2, K Ohara2, H Hata3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26372833     DOI： 10.1111/jdv.13331

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  3 in total

1.  Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'.

Authors:  Keisuke Imafuku; Koji Yoshino; Kei Yamaguchi; Satoshi Tsuboi; Kuniaki Ohara; Hiroo Hata
Journal:  Br J Cancer       Date:  2017-03-21       Impact factor: 7.640

Review 2.  Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.

Authors:  Chun-Bing Chen; Ming-Ying Wu; Chau Yee Ng; Chun-Wei Lu; Jennifer Wu; Pei-Han Kao; Chan-Keng Yang; Meng-Ting Peng; Chen-Yang Huang; Wen-Cheng Chang; Rosaline Chung-Yee Hui; Chih-Hsun Yang; Shun-Fa Yang; Wen-Hung Chung; Shih-Chi Su
Journal:  Cancer Manag Res       Date:  2018-05-17       Impact factor: 3.989

3.  Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan.

Authors:  H Uhara; Y Kiyohara; A Tsuda; M Takata; N Yamazaki
Journal:  Clin Transl Oncol       Date:  2017-07-03       Impact factor: 3.405
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.